Emmaus Life Sciences Posts 2025 Annual Results
Emmaus Life Sciences Reports Annual Financial Results
TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025.
Emmaus Life Sciences, a biopharmaceutical company specializing in sickle cell disease treatment, released its 2025 financial results. The OTCQB-listed firm reported on its operational performance and financial condition for the year ending December 31, 2025. The announcement marks the company's latest update on its commercial-stage initiatives.
Explore More
Related News
Unlocking Replicability: The Seven-Year Journey in Social Sciences | Science-Environment
Devdiscourse · 2026.04.04
Longtime leader in health sciences education appointed dean of Mizzou’s College of Health Sciences
Show Me Mizzou · 2026.04.03
BRUNO KARSENTI JOINS SCIENCES PO
2026.04.03
BREAKING: MTSU mathematical sciences professor dead
Sidelines | Middle Tennessee State University’s Digital News Source · 2026.04.03
Local science students invited to National Competition
paNOW · 2026.04.05
Galactic Explosions and Lunar Expeditions: A New Era in Space Science | Science-Environment
Devdiscourse · 2026.04.05